NextCure to Merge with Avere Therapeutics in $320M Deal
Event summary
- NextCure announced a merger with Avere Therapeutics, expected to close in H2 2026.
- Avere raised $320M in private financing ahead of the all-stock transaction.
- NextCure's cash position dropped from $41.8M to $20.1M QoQ due to restructuring and operations.
- LNCB74 development transferred to LigaChem under a continuation agreement.
The big picture
NextCure's merger with Avere Therapeutics reflects a broader trend of cash-strapped biotechs consolidating to extend runway and refocus portfolios. The deal underscores the strategic pivot from oncology (NextCure) to inflammatory diseases (Avere), while NextCure shareholders retain exposure via contingent value rights tied to legacy assets.
What we're watching
- Merger Execution
- Whether NextCure can successfully close the merger by year-end amid regulatory and shareholder hurdles.
- Asset Monetization
- How NextCure preserves value for legacy assets like SIM0505 during the transition.
- Financial Runway
- The pace at which Avere Therapeutics deploys its $320M war chest to advance pipeline programs.
Related topics